Form D · Biotechnology
Ocugen, Inc.
Malvern, PA · CIK 0001372299
Offering snapshot reported May 7, 2020 · SEC filing
- Reported sold
- $395 Offering amount: $395
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 22, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 7, 2020 | Initial | $395 | No comparison | 1 | SEC filing |
| May 7, 2020 | Initial | $14,283,724 | No comparison | 6 | SEC filing |
| Oct 12, 2016 | Initial | $30,000,001 | No comparison | 20 | SEC filing |
| Jan 6, 2014 | Initial | $10,323,988 | No comparison | 17 | SEC filing |
| Nov 26, 2012 | Amendment | $37,638,679 | $150,000vs Jul 27, 2012 | 13 | SEC filing |
| Jul 27, 2012 | Initial | $37,488,679 | No comparison | 12 | SEC filing |
| May 26, 2011 | Initial | $34,300,000 | No comparison | 15 | SEC filing |
| Aug 5, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Aug 7, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-366492
Source: Form D, filed May 7, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kirk Andriano | Executive |
| Rasappa Arumugham | Executive |
| Joshua Baltzell | Director |
| Kelly Beck | Executive |
| Brian Callahan | Executive |
| Kristen Castillo | Director |
| Prabhavathi Fernandes | Director |
| Patrick Fortune | Director |
| David Gill | Director |
| Peter Greenleaf | Director, Executive |
| Adam Gridley | Director, Executive |
| John J. Johnson | Director |
| Daniel Jorgensen | Executive |
| Uday B Kompella | Director |
| Garheng Kong | Director |
| Garheng Kong, M.D., Ph.D | Director |
| Garheng Kong, M.D., Ph.D. | Director |
| Ramesh Kumar | Director |
| Michael Lewis | Director |
| Jonathan Lieber | Director |
| Kevin Mc Ardle | Executive |
| Shankar Musunuri | Director, Executive |
| Patrick O'donnell | Director, Executive |
| Manish Potti | Director |
| Philip Press | Director |
| Kevin Rakin | Director |
| Dominic Redfern | Director |
| Harry Rein | Director |
| Sanjay Subramanian | Executive |
| Vijay Tammara | Executive |
| Laurence J.B. Tarrant | Executive |
| Suha Taspolatoglu | Director |
| Junge Zhang | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
5 Great Valley Parkway Suite 160
Malvern, PA, 19355
Malvern, PA, 19355